Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardia
Pritchett, E.L.; Hammill, S.C.; Reiter, M.J.; Lee, K.L.; McCarthy, E.A.; Zimmerman, J.M.; Shand, D.G.
American Journal of Cardiology 52(8): 1007-1012
1983
ISSN/ISBN: 0002-9149 PMID: 6356859 DOI: 10.1016/0002-9149(83)90521-0Document Number: 521905
Spontaneous variability in the occurrence of paroxysmal arrhythmias has made it difficult to apply objective and quantitative methods to describe their clinical course. In this study of paroxysmal atrial tachycardia, the "tachycardia-free interval" was used as a quantitative measure of drug efficacy during treatment with oral verapamil. The tachycardia-free interval is the time a patient remains free from an episode of tachycardia after drug treatment is begun. We documented recurrent tachycardia by telephone transmission of the electrocardiogram. Improvement caused by increasing the drug dose (360 versus 480 mg/day) or by comparing verapamil with placebo treatment was demonstrated by upward shifts in the cumulative tachycardia-free interval curves. The tachycardia-free interval is an easily measured clinical variable that has substantial promise in the study of paroxysmal arrhythmias.